ValiRx Plc (VAL) Receives “Speculative Buy” Rating from Beaufort Securities
ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reissued by investment analysts at Beaufort Securities in a note issued to investors on Friday. They currently have a GBX 6.50 ($0.09) price objective on the stock.
Shares of ValiRx Plc (LON:VAL) traded down 6.98% during trading on Friday, reaching GBX 1.00. The company’s stock had a trading volume of 1,724,105 shares. The company’s market capitalization is GBX 1.44 million. ValiRx Plc has a one year low of GBX 0.95 and a one year high of GBX 7.88. The firm’s 50-day moving average price is GBX 1.37 and its 200-day moving average price is GBX 1.95.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.